Interleukin-1 receptor type II - Immunex

Drug Profile

Interleukin-1 receptor type II - Immunex

Alternative Names: IL-1RII - Amgen; Interleukin-1 receptor type 2 - Amgen; Soluble interleukin-1 receptor type II - Amgen

Latest Information Update: 10 Sep 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunex
  • Class Antirheumatics
  • Mechanism of Action Interleukin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 24 Sep 2002 A clinical study has been added to the adverse events and pharmacokinetics sections
  • 24 Jul 2002 Immunex has been acquired by, and merged into, Amgen
  • 31 Dec 2001 Phase-I clinical trials for Rheumatoid arthritis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top